Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix and IrsiCaixa Expand RNAi Research to Hepatitis C

NEW YORK, March 23 (GenomeWeb News) - Acacia Research's CombiMatrix unit and researchers at the IrsiCaixa Foundation in Spain have expanded their RNAi collaboration to include hepatitis C, Acacia said today.


Under the expanded agreement, scientists led by Bonaventura Clotet will screen pooled siRNA compounds provided by CombiMatrix for efficacy against the hepatitis C virus.


The IrsiCaixa researchers, based in Barcelona, Spain, have already been testing siRNA compounds from CombiMatrix on HIV since last year.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.